We are live on ! Find out more
VRX

VALEANT PHARMACEUTICALS INTL
VRX

Delisted

VRX was delisted on the 27th of September, 2010.

Back to rankings

3 hedge funds and large institutions have $2.7M invested in VALEANT PHARMACEUTICALS INTL in 2013 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more capital invested

Capital invested by funds: $846K → $2.7M (+$1.85M)

50% more funds holding

Funds holding: 2 → 3 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAA
Peregrine Asset Advisers
Oregon
+$1.85M
2
TWA
TCI Wealth Advisors
Arizona
+$12.8K

Top Sellers

Rank Fund Capital Flow
1
LWI
Long Wharf Investors
Massachusetts
-$193K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAA
1
Peregrine Asset Advisers
Oregon
$1.85M +$1.85M +17,775 New
LWI
2
Long Wharf Investors
Massachusetts
$829K -$193K -1,847 -19%
TWA
3
TCI Wealth Advisors
Arizona
$16K +$12.8K +126 +406%

VRX Hedge Fund Activity: Q3 2013 in Review

3 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q3 2013, worth a combined $2.7M — up 219% from $846K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new VRX positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Peregrine Asset Advisers, opening a new position worth an estimated $1.85M. The largest seller was Long Wharf Investors, cutting an estimated $193K.

  • 3 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q3 2013, up from 2 in Q2 2013.
  • Funds reported $2.7M of VALEANT PHARMACEUTICALS INTL stock for Q3 2013, up 219% quarter-over-quarter.
  • 1 fund opened new VALEANT PHARMACEUTICALS INTL positions in Q3 2013 and 0 closed out, a net change of +1 holder.
  • The largest VALEANT PHARMACEUTICALS INTL buyer in Q3 2013 was Peregrine Asset Advisers, an estimated $1.85M added.
  • The largest VALEANT PHARMACEUTICALS INTL seller in Q3 2013 was Long Wharf Investors, an estimated $193K sold.

Based on aggregated 13F filings for Q3 2013.